Show simple item record

dc.contributor.authorSabour-Pickett, S
dc.contributor.authorLoughman, J
dc.contributor.authorNolan, J M
dc.contributor.authorStack, J
dc.contributor.authorPesudovs, Konrad
dc.contributor.authorMeagher, K A
dc.contributor.authorBeatty, S
dc.date.accessioned2016-12-21T02:50:28Z
dc.date.available2016-12-21T02:50:28Z
dc.date.issued2013
dc.identifier.citationSarah Sabour-Pickett, James Loughman, John M. Nolan, et al., “Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab,” Journal of Ophthalmology, vol. 2013, Article ID 268438, 7 pages, 2013. doi:10.1155/2013/268438en
dc.identifier.issn2090-004X
dc.identifier.urihttp://hdl.handle.net/2328/36874
dc.descriptionThis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.description.abstractPurpose. To assess visual function and its response to serial intravitreal ranibizumab (Lucentis, Genentech) in patients with neovascular age-related macular degeneration (nv-AMD). Methods. Forty-seven eyes of 47 patients with nv-AMD, and corrected distance visual acuity (CDVA) logMAR 0.7 or better, undergoing intravitreal injections of ranibizumab, were enrolled into this prospective study. Visual function was assessed using a range of psychophysical tests, while mean foveal thickness (MFT) was determined by optical coherence tomography (OCT). Results. Group mean (±sd) MFT reduced significantly from baseline (233 (±59)) to exit (205 (±40)) ( ). CDVA exhibited no change between baseline and exit visits ( and , resp.). Measures of visual function that did exhibit statistically significant improvements ( for all) included reading acuity, reading speed, mesopic and photopic contrast sensitivity (CS), mesopic and photopic glare disability (GD), and retinotopic ocular sensitivity (ROS) at all eccentricities. Conclusion. Eyes with nv-AMD undergoing intravitreal ranibizumab injections exhibit improvements in many parameters of visual function. Outcome measures other than CDVA, such as CS, GD, and ROS, should not only be considered in the design of studies investigating nv-AMD, but also in treatment and retreatment strategies for patients with the condition.en
dc.language.isoen
dc.publisherHindawi Publishing Corporationen
dc.rightsCopyright © 2013 Sarah Sabour-Pickett et al.en
dc.subjectMacular Degenerationen
dc.subjectIntravitreal Ranibizumaben
dc.subjectOphthalmologyen
dc.titleVisual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumaben
dc.typeArticleen
dc.identifier.doihttps://doi.org/10.1155/2013/268438en
dc.rights.holderSarah Sabour-Pickett et al.en
dc.rights.licenseCC-BY


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record